The yeast MAPKKK Ste11 activates three MAP kinase pathways, including pheromone signaling, osmosensing, and pseudohyphal/invasive growth pathways. We identified two chemical compounds, BTB03006 and GK03225, that suppress growth defects induced by Ste11 activation in diploid yeast cells. BTB03006, but not GK03225, was found to suppress growth defects induced by both -factor and Ste4 G overexpression in the pheromone signaling pathway, suggesting that GK03225 is an osmosensing pathway-specific inhibitor. We also performed genome-wide suppressor analysis for Ste11 activation, using a yeast deletion strains collection, and identified PBS2 and HOG1, and several genes associated with chaperone functions, which represent potential target proteins of the drugs screened from Ste11 activation. GK03225 possesses an Iressa-like quinazoline ring structure, and its chemical analog, 11N-078, suppresses c-Abl human tyrosine kinase activity. These results suggest that drug screening in yeast can identify human tyrosine kinase inhibitors and other drugs for human diseases.
lates both serine/threonine and tyrosine), and some have now been found to be involved in cancer development. 1) An example includes the oncogene v-src, encoding a protein-tyrosine kinase that activates the downstream mitogen-activated protein kinase (MAPK) signaling pathways. 2, 3) The MAPK signaling pathways in turn consist of both protein serine/threonine and dualspecificity kinases, such as MAP kinase kinase kinase (MAPKKK), MAP kinase kinase (MAPKK), and MAP kinase (MAPK). MAPKKK phosphorylates and activates MAPKK, which then phosphorylates and activates MAPK. Activated MAPK then phosphorylates downstream protein targets, thus mediating the flow of upstream signals to their downstream effectors. 4) In cancer cells, specific signaling pathways such as these often become constitutively active, resulting in unregulated cellular proliferation. Hence, inactivation of a specific protein kinase or a specific signaling pathway that plays a critical role in tumorigenesis has the potential to be utilized as a novel target for the development of cancer drug therapies.
Recently, various protein kinase inhibitors have been successfully developed for cancer therapy. Gleevec (Imatinib, STI-571) is one such example. It is used to treat patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Gefitinib (Iressa, ZD1839) is another kinase inhibitor, used in the treatment of lung cancer. These two agents are among the first examples of target-directed drugs that prevent the activity of a specific protein kinase by competing with ATP. [5] [6] [7] The specificity of these compounds is the most important factor in this case, as there are many other similar protein kinases that play vital roles in normal cellular functions. 3) Hence the development of screening systems for novel compounds that act on a specific protein kinase or against a protein that operates in a specific signaling pathway should facilitate a faster and more reliable drug development process.
The budding yeast Saccharomyces cerevisiae, a unicellular eukaryotic microorganism, has been commonly used for drug development due to the presence of evolutionally conserved cellular functions, including the MAPK signaling pathways. [8] [9] [10] [11] [12] The yeast MAPKKK, Ste11, is known to activate three signaling pathways involved in pheromone signaling, osmosensing, and pseudohyphal/invasive growth in response to different stimuli ( Fig. 1) . 4) The pheromone signaling and pseudohyphal/invasive growth pathways share the same downstream components, Ste7 MAPKK and Kss1/Fus3 MAPK, whereas the osmosensing pathway alternatively utilizes Pbs2 MAPKK and Hog1 MAPK. 4) Ste11 is a serine/threonine kinase that contains both regulatory and catalytic regions. Mutations or deletion of the Nterminal regulatory region of this protein converts it to a constitutively active form, and thus activates downstream pathways. [13] [14] [15] In diploid yeast cells, activated Ste11 stimulates osmosensing and pseudohyphal growth pathways only, due to the absence of a pheromone signaling pathway in these cells, but all three of these pathways are activated in haploid yeast (Fig. 1) . As a consequence of this, the activation and inactivation of specific signaling pathways can be manipulated in budding yeast via mutations and by overexpressing genes encoding components of those pathways. Hence, when a mutant STE11 is overexpressed in diploid, yeast growth is inhibited due to overactivation of the ploidynonspecific pathways. [13] [14] [15] [16] [17] In our current study, we utilized this growth phenotype to screen for inhibitors of specific signaling pathways.
When Ste11-activated signaling pathways are utilized for screening, each of the components associated with Ste11 activation and its downstream signaling pathways can be tested as targets of novel inhibitors. To identify novel target proteins, genome-wide genetic analysis is often a promising approach, as most genes can be analyzed by this method. For example, yeast genes relating to human diseases such as -synuclein, huntingtin fragments, and RNA viruses have been screened in this way. [18] [19] [20] [21] [22] Hence we reasoned that if a mutant STE11 gene is expressed in a library of yeast deletion mutants, any strains that suppress STE11-induced growth defects, and hence the specific genes involved, can be identified.
We have also established a yeast assay system to detect inhibitors of human protein kinases. Human c-Abl protein-tyrosine kinase is known to be fused to the BCR protein in Philadelphia chromosome-positive human leukemias. 23) Overexpression of c-Abl in Schizosaccharomyces pombe causes tyrosine-phosphorylation of various proteins and also results in growth defects. 24) In this study, we expressed c-Abl in S. cerevisiae and observed a similar phenotype. One chemical analog of a screened compound was found to suppress c-Abl activation in yeast. We contend, therefore, that the combination of drug screening using in vivo mammalian tyrosine kinase assays and genome-wide genetic analyses in yeast is an effective methodology in the preliminary stages of drug development.
Materials and Methods
Strains, plasmids, and media. The yeast strains used in this study were W303-1A haploid (MATa ade2-1 trp1-1 his3-11 leu2-3 ura3-1 can1-100), W303 diploid (MATa/MAT ade2-1/ade2-1 trp1-1/trp1-1 his3-11/ his3-11 leu2-3/leu2-3 ura3-1/ura3-1 can1-100/can1-100), and BY4743 diploid (MATa/MAT leu2Á0/leu2Á0 ura3Á0/ura3Á0 his3Á200/his3Á200 met15Á0/MET15 lys2Á0/LYS2). Homozygous diploid deletion strains were obtained from Research Genetics (#95401.H1R3: Huntsville, AL). RAK21 (bar1::HIS3) was also used in the pheromone signaling assay. 25) A 7.0-kb BamHI-SalI fragment containing the STE11-4 dominant mutant gene in the pSL1509 vector 13) was inserted into the pRS313 vector, 26) resulting in p313STE11-4. A 3.0-kb fragment containing the STE11-4 open reading frame was amplified by PCR with primer STE11-1 (ggggatccacatggaacagacacaaac) and also a vector primer for p313STE11-4. The amplicon was then digested with BamHI and XbaI, and inserted into Three MAP kinase pathways in yeast share Ste11 as a common MAPKKK. The pheromone response pathway is haploid-specific but the osmosensing, and the pseudohyphal/invasive growth pathways are ploidy nonspecific. In haploid, Ste11 activates all three pathways, but not the pheromone response pathway in diploid.
the BamHI-XbaI sites of YEp51B, 27) resulting in pGALSTE11-D53. The pL19LEU2 plasmid containing STE4 was constructed by inserting a 2.1-kb XhoI-SalI fragment containing LEU2 from YEp13 into the SalI site of pL19. 28) Human c-Abl was amplified by PCR with primers cctaggatccaaaatgcccaaccttttcgttgcactgtatgattttg and actagtcgactctagatcagttgtttccccagctccttttccac using a cDNA library produced from human thymus (#9517, Takara Bio, Shiga, Japan) as a template. The amplified fragments were then inserted into pYES2/CT (Invitrogen, Carlsbad, CA), resulting in pYEScAbl. A AscI-NotI fragment containing the GAL promoter was amplified by PCR with primers GAL10SacI (aaagagctcatcgcttcgctgatta) and GALpASCNOT (ttttgcggccgccattggcgcgccttatattgaattttcaaaaattcttacttt) from p316GAL, 29) and inserted into the SacI and NotI sites of pRS316 to generate p316GALASC. A c-Abl fragment was amplified from pYEScAbl with primers ASCAbl-1 (ggcgcgccaatgcccaaccttttcg) and NOTAblc1 (tttgcggccgcctattgtttccccagctcc), and inserted into the AscI and NotI sites of p316GALASC to form p316GALASCAbl. A cAblÁSH3 fragment was amplified from pYEScAbl with primers AbldSH3-1 (ggcgcgccatgacgccagtcaac) and NOTAblc1, and inserted into the AscI-NotI sites of p316GALASC to generate p316GALASCAblÁSH3. YPD medium and other synthetic media were prepared by standard protocols. 30) Galactose and galactose/raffinose synthetic media contained 2% galactose and 2% galactose with 2% raffinose instead of 2% glucose respectively. For drug assays, synthetic medium containing 1% instead of 2% agar was prepared, as the growth of embedded cells was found to be better in soft agar. YPD plates containing 0.9 and 1 M NaCl or 1 M sorbitol were also prepared.
Chemical compounds. All chemical compounds were dissolved in dimethylsulfoxide (DMSO). A chemical library containing about 8,000 compounds (1 mM: Maybridge Chemical Company, Cornwall, UK) was then used for screening. Radicicol and PD153035 were purchased from Calbiochem (EMD Biosciences, San Diego, CA). GK03225, GK03474, GK03232, and BTB03006 were purchased from Maybridge. 11N-058, 11N-821, 11N-806, 11N-066, 11N-070, 11N-076, 11N-812, 11N-060, 11N-084, 11N-068, 11N-089, 11N-078, 11N-061, 11N-112, 12N-006, 11N-820, 11N-823, and 10N-666S were purchased from Bionet Research (Key Organics, Cornwall, UK), and P2001S-075163 and P2000S-28024 were purchased from Phameks (Moscow, Russia). The -mating factor (Peptide Institute, Osaka, Japan) was dissolved in water at a concentration of 1 mg/ml. Drug screening. For drug screening, the W303 diploid strain was transformed with pGALSTE11-D53, and the cells were grown in leucine-dropout glucose synthetic medium. The cell concentrations were measured with a photometer and the cells were then mixed in pre-melted leucine-dropout galactose medium containing 1% agar to a final cell concentration of 0.001 at OD 600 . This cellagar mixture was then prepared in solid-plate form, and 3.5 ml of each compound was spotted on it. The plates were incubated at the indicated temperatures. For screening, the plates were incubated at 28 C for 2 d and then at 32 C for 3 d. The W303-1A strain was transformed with pL19LEU2 and the agar assay plates were prepared similarly to test for suppression of STE4-induced growth arrest. For the -factor assay, the RAK21 strain was grown in synthetic medium and the cells were mixed with pre-melted synthetic medium supplemented with the required nutrients, together with -factor, to give a final concentration of 0.1 mg/ml.
To examine the effect of drugs on the osmosensing pathway, 200 ml of W303 diploid cells at a cell concentration of 0.01 at OD 600 was spread onto YPD, YPD + 0.9 M NaCl, and YPD + 1 M sorbitol plates. Then 5 ml each of DMSO, 10 mM GK03225, and 10 mM 11N-078 were spotted. The YPD and sorbitol plates were incubated at 28 C for 3 d, and NaCl plate for 6 d.
Genome-wide analysis of Ste11 suppressers. Systematic yeast transformation of the deletion strains collection was performed as follows: Yeast deletion strains were grown on YPD square plates, picked with 96-pin QReps (X5052, Genetix, Hampshire, UK), and transferred to 96-well microplates containing 25 ml of YPD liquid medium. The microplates were then incubated for 24 h without shaking. To each well of the cultures, 45 ml of transformation solution containing plasmid DNA (43.7% polyethylene glycol 3350, 217 mM lithium acetate, 109 mM dithiothreitol) 31) was added directly. The plates were vortexed and incubated at 42 C for 2 h. Ten-ml aliquots of the mixtures were then spotted onto selection plates using a 96-channel pipetting machine (HT Station 500, Cosmotec, Tokyo). The plates were incubated at 28 C for 3-4 d. Transformants that appeared on the selection plates were transferred to 96-well microplates containing synthetic dropout medium and incubated without shaking for 1 d. The cells were then spotted onto synthetic glucose (repressed) and galactose (overexpressed) plates. Deletion strains that grew on galactose plates were then picked and analyzed.
c-Abl expression in yeast. The BY4743 strain was transformed with c-Abl expression plasmids, and the resulting transformants were spotted onto either glucose or galactose plates. For screening of c-Abl sensitive strains, 26 strains harboring deletions in protein phosphatases (cmp2Á, cna1Á, ltp1Á, mih1Á, msg5Á, oca1Á, pph21Á, pph22Á, pph3Á, pps1Á, ppt1Á, ppz1Á, ppz2Á, ptc3Á, ptp5Á, ptp1Á, ptp2Á, ptp3Á, sal6Á, sdp1Á, siw14Á, tep1Á, ymr1Á, yvh1Á, ycr079wÁ, and ygr203wÁ) were picked and transformed with cAbl plasmids. Cell growth was then observed by spotting transformants onto galactose plates. For drug assays of c-Abl, the BY4743 strain was transformed with c-Abl plasmid and grown in uracil-dropout medium. The cells in this instance were mixed in pre-melted uracildropout galactose/raffinose medium containing 1% agar to a final cell concentration of 0.001 at OD 600 , and these cell-agar mixtures was prepared as solid plates. Five ml of each of the compounds to be tested was then spotted onto these plates.
Western blotting analysis. c-Abl-transformed cells were incubated in synthetic galactose medium for 4.5-5 h, centrifuged, mixed with SDS sample buffer (2% SDS, 20 mM Tris-HCl, 5% 2-mercaptoethanol, 10% glycerol, 0.0012% bromophenol blue), heated at 95 C for 10 min, and subjected to SDS-PAGE. The resolved proteins were blotted onto PVDF membranes, soaked in blocking buffer, and mixed with either anti-phosphotyrosine mouse monoclonal antibody (#05-321, Upstate, Lake Placid, NY) or anti-actin antibody (#sc-1616, Santa Cruz Biotechnology, Santa Cruz, CA). The membranes were subsequently incubated with peroxidase-conjugated affinipure goat anti-mouse and antirabbit antibodies respectively (Jackson Immunoresearch Laboratories, West Grove, PA). Reactions were visualized by SuperSignal West Pico chemiluminescent substrate (Pierce Biotechnology, Rockford, IL), and detected with a Lumino image analyzer LAS-1000 (Fujifilm, Tokyo).
Results

Screening of Ste11 signaling inhibitors in diploid yeast
MAPKKK Ste11 mutant STE11-4, in which the threonine-596 residue located within the catalytic domain was replaced with isoleucine, constitutively activates the downstream pathways of Ste11. 13) Hence we constructed a galactose-inducible STE11-4 gene (pGALSTE11-D53) for use in our screening analyses. Initially we used diploid yeast for our screening, as STE11 expression results in the activation of osmosensing and pseudohyphal growth signaling pathways, but not the pheromone signal pathway, in these cells. STE11-4 overexpression showed temperature-dependent growth defects. When the cells were incubated at 28 C, strong growth defects were observed which were alleviated at higher temperatures ( Fig. 2A) . This may be due to temperature effects on the active structure formation of the Ste11 protein, as interaction between Ste11 with Hsp90 chaperones has been reported. 32) We predicted that the strength of the growth defects induced by STE11 would affect drug sensitivity. Hence, to determine the optimal growth conditions for drug screening using this STE11-4 overexpression system, we examined the sensitivity of these cells to radicicol, which is known to inhibit Hsp90 function 33, 34) and regulate mammalian MAPKKK raf-1 in yeast. 35) Radicicol was spotted onto galactose medium containing STE11-4 transformed cells and the incubation temperature was varied. The incubation temperature was indeed found significantly to affect the size of the emerging halos (Fig. 2B) . Maybridge Chemical Library compounds (1 mM each) were spotted onto our screening plates, and agents GK03225 and BTB03006 were positively identified as Ste11 inhibitors from a total panel of 8,266 compounds (Fig. 3) .
The effects of screened Ste11 signaling inhibitors on the pheromone signaling pathway
To examine whether the Ste11 signaling inhibitors that we identified would suppress the pheromone signaling pathway, the MATa bar1 deletion yeast strain, which is hypersensitive to -factor pheromone, was embedded in -factor-containing agar medium. In addition, an STE4 overexpression plasmid (pL19LEU2) was transformed into the W303-1A haploid yeast strain, and the transformed cells were then embedded into galactose agar plates. We performed this experiment because overexpression of STE4, encoding a subunit of a heterotrimeric G protein, is known to cause growth arrest by activating pheromone signaling.
28) GK03225 and BTB03006 were spotted onto these plates, and incubations were performed at 28 C (Fig. 3) . We observed that BTB03006, but not GK03225, suppressed the growth arrest caused by both -factor and STE4. But these compounds did not suppress any of the growth defects caused by overexpression of other genes, including BOI1, TPK3, and BNI1 (data not shown), indicating that these inhibitors are specific to Ste11. From these results, we speculated that BTB03006 is a Ste11 kinase inhibitor or an inhibitor of a protein associated with Ste11 activation. On the other hand, GK03225 appears to be a pathway-specific inhibitor that acts on ploidy-nonspecific pathways but not on the pheromone signaling pathway. Our data also suggest that GK03225 is not an inhibitor of Ste11 per se, because in this case, activation of the pheromone Overexpression in Yeast. A, The BY4743 yeast strain was transformed with a STE11-4 dominant mutant under the control of a galactose inducible promoter or with an empty vector control. The transformants were diluted, spotted on galactose plates, and incubated at the indicated temperatures. B, The W303 strain transformed with STE11-4 plasmid was embedded in 1% soft agar medium plates containing galactose. Five ml of 1 mM radicicol was spotted onto the plates, which were then incubated at the indicated temperatures. Bars, 10 mm. pathways would also have been suppressed. Therefore, Ste11 inhibitor screening in diploid yeast cells identified two distinct types of compounds, one that might act directly on Ste11 and another that might act on a component in the ploidy-nonspecific pathways (Fig. 1) .
Genome-wide analysis of STE11 suppressors
In our drug-screening strategy, the target proteins were expected to be components of Ste11-associated signaling pathways or required factors for the expression of the Ste11 gene. Gene deletions of any of these proteins should consequently suppress the growth defects induced by STE11 activation, if they are themselves nonessential for growth. To elucidate these target candidates, we transformed an STE11 plasmid into a panel of about 4,800 nonessential deletion strains, and screened for suppressors by incubating the transformants at 28 C for 1 d and then at 32 C for 4 d. Of the 4,433 strains that were transformed successfully, 161 were initially screened. These candidate deletion strains were GK03225 and BTB03006 were identified from our screen for Ste11 signaling inhibitors. W303 diploid and W303-1A haploid budding yeast strains were transformed with STE11-4 plasmid (pGALSTE11-D53) and STE4 plasmid (pL19LEU2) respectively, and embedded in galactoseagar medium. The RAK21 (bar1::HIS3) strain was embedded in glucose-agar medium containing 0.1 mg/ml of -factor. These cell-embedded agar plates were then spotted with 5 ml of 10 mM GK03225 and 1 mM BTB03006, as shown, and incubated at the indicated temperatures. Homozygous diploid deletion strains were transformed with STE11-4 plasmid, and 22 deletion strains were subsequently identified from 4,433 strains as suppressors of the growth defects caused by STE11-4 expression. These 22 deletion strains were then transformed with either STE11-4 (pGALSTE11-D53) or BOI1ÁN (pGA68) plasmid and spotted on glucose (Glc), galactose (Gal), or galactose/raffinose (Gal+Raf) plates. The strains that also showed BOI1ÁN suppression were not regarded as STE11-specific suppressors. These deletion strains were also spotted on YPD medium containing 1 M NaCl.
transformed again with the same plasmid, and growth suppression was examined. Twenty-two deletion strains were finally identified as Ste11 suppressors (Fig. 4) . To distinguish Ste11 functional suppressors from defects in gene expression, we proceeded to transform a BOI1ÁN overexpression construct (pGA68) 27) into these selected strains. Many of the resulting transformants showed similar levels of suppression of the growth defects characteristic of BOI1ÁN expression, suggesting that these strains were not specific to STE11. In fact, the gal2, gal3, and gal4 deletion strains, in which the galactoseinducible expression pathway is inactive, were included in this group. Although there is a possibility that Boi1 functions in the same pathway as Ste11, at least six of our screened deletion strains (pbs2, hog1, hsc82, ygl072c/hsf1ÁC, sti1, and bud27) were found to be Ste11-specific suppressors. Among these mutants, only the pbs2 and hog1 deletion strains were observed to be sensitive to 1 M NaCl, indicating that the other strains did not harbor defects in the osmosensing pathway.
Effects of GK03225 analogs
The structure of GK03225 is similar to that of PD153035, a known tyrosine-kinase inhibitor.
36) The drug assay system developed in this study can easily be used to test other compounds. Hence we obtained 23 structural analogs of GK03225 and examined their suppression activity (Table 1, Fig. 5A ). Eight compounds showed growth suppression, and 11N-078 suppressed Ste11 activation to a greater extent than GK03225 (Fig. 5A) .
In the ploidy-nonspecific pathways (Fig. 1 ), Pbs2 and Hog1 are the only known downstream components that are not present in the pheromone signaling pathway. Hence we examined the effect of drugs on the osmosensing pathway. Cells were spread on highosmolarity plates, and then GK03225 and 11N-078 were spotted (Fig. 5B) . 11N-078 showed a slightly larger halo of growth defects on the high-osmolarity plates, suggesting that 11N-078 is an inhibitor of a component in the osmosensing pathway.
Effects of STE11 pathway inhibitors on c-Abl tyrosine kinase activity in yeast GK03225, 11N-078, and PD153035 contain a quinazoline ring structure in common, and are hence expected to be active tyrosine kinase inhibitors. Hence we constructed a drug assay system using c-Abl tyrosine kinase activity in yeast. c-Abl, encoding SH3, SH2, and kinase regions, was amplified by PCR from a human cDNA library and inserted downstream of a galactoseinducible promoter in a yeast construct (pYEScAbl).
To test the effects of deleting the SH3 domain, p316GALASCAbl and p316ASCAblÁSH3 were also constructed. Expression of the SH3 deleted c-Abl protein product showed only weak growth defects in yeast (Fig. 6A) , although deletion of this region has been reported to elicit elevated phosphorylation in mammalian cells. 37) Tyrosine phosphorylation by the expression of v-Src protein kinase in yeast is known to be dephosphorylated by a yeast protein phosphatase. 38) Identification of yeast protein phosphatases that target the tyrosine-phosphorylated substrates of c-Abl should improve the sensitivity of the tyrosine kinase assay in yeast. Hence we transformed c-Abl plasmids into the 26 phosphatase deletion strains and analyzed the resulting transformants for cAbl-induced growth defects. Among these transformants, only the ptp1Á deletion strain showed greater growth defects on the overexpression of c-Abl or cAblÁSH3 (Fig. 6A) . In addition, tyrosine-phosphorylation was found to be enhanced in the ptp1Á strain A, GK03225 analogs were assayed by spotting them onto plates embedded with STE11-4 expressing cells. B, GK03225, 11N-078, and DMSO were spotted onto cell-YPD plates containing 0.9 M NaCl or 1 M sorbitol, as indicated. A 5-ml aliquot of each compound was spotted at a concentration of 10 mM. W303 diploid cells were used. (Fig. 6B) . These results indicate that Ptp1 is the only major tyrosine phosphatase that targets the phosphorylated substrates of c-Abl in yeast.
Using the c-Abl tyrosine kinase assay system in yeast, we examined the suppression activity of GK03225 analogs. The cells were transformed with the c-Abl plasmid pYEScAbl and embedded in galactose/raffinose agar medium. This was followed by drug spotting. Of the 24 compounds that were tested in this experiment, only 11N-078 showed appreciable suppression of c-Abl-induced growth defects (Fig. 6C) . To confirm this inhibition of tyrosine phosphorylation in yeast, tyrosine-phosphorylated proteins were detected by western blotting with an anti-phospho-tyrosine antibody. 11N-078 was indeed found to inhibit c-Abl-induced protein tyrosine phosphorylation (Fig. 6D) . The 11N-070 analog also showed inhibition of tyrosine phosphorylation, although we did not detect any suppression phenotype in our yeast growth assay for this compound. The data thus indicates that 11N-078 inhibits both the Ste11 signaling pathway and c-Abl tyrosine kinase activity in yeast.
Discussion
In this report, we describe the establishment of a drug screening system using MAPKKK Ste11 as the target, as this kinase plays a role in three separate signaling pathways that respond to different stimuli. Overexpression of a dominant STE11-4 mutant in yeast caused growth defects that were temperature sensitive ( Fig. 2A) . This is consistent with previous findings showing that heat-shock chaperones are involved in Ste11 activation. 32, 39, 40) Hence this temperature sensitivity might be caused by defects in active Ste11 structure formation at high temperatures. In practical terms, this phenotype is very useful for drug screening A, BY4743 wild-type and ptp1Á strains were transformed with p316GALASCAbl (c-Abl), p316GALASCAblÁSH3 (c-AblÁSH3), or a control vector. The transformants were then diluted and spotted onto glucose (Glc) or galactose (Gal) plates. B, BY4743 and ptp1Á strains were transformed with p316GALASCAbl and incubated in galactose medium for 4.5 h. Tyrosine phosphorylation was detected by anti phosphotyrosine antibodies. C, The BY4743 strain was transformed with pYEScAbl and embedded in galactose/raffinose medium plates. Five ml of a 10 mM concentration of 11N-078 was spotted onto the center of the plate, which was then incubated at 28 C for 6 d. D, Cells of the BY4743 strain transformed with p316GALASCAbl were incubated in galactose medium together with GK03225 analogs (50 mM) for 5 h. Tyrosine phosphorylation activities were then analyzed.
as the sensitivity to specific agents is much higher in STE11-transformed cells that are incubated at higher temperatures. Indeed, as shown by our treatments with radicicol, the growth halo of suppression in the transformed yeast cells was clearer at high temperatures (Fig. 2B) . Drug sensitivity assays in yeast have been improved by the deletion of pleiotropic drug resistance genes, but these deletions are usually specific to related but not diverse compounds. 41) Therefore, the use of submarginal expression of growth inhibitory genes 27) leading to subtle growth defects can be used for sensitive and wider drug assay. In addition, the growth halo size is a measure of the strength of the suppression effects, and a clear halo inside the spot, which we observed for BTB03006, indicates that this agent exerts toxic effects on normal cell growth (Fig. 3) . A similar growth halo assay was established previously for the isolation of Ca 2þ -signaling pathway inhibitors. 9) Our current use of a halo assay in yeast cells with submarginal growth has given us valuable information regarding the intensity, toxicity, and appropriate inhibitory concentrations of the drugs being tested.
Another novel feature of our screening system is the use of MAPKKK Ste11. In haploid yeast, Ste11 overexpression leads to the activation of pheromone signaling, osmosensing, and pseudohyphal/invasive growth pathways, but in diploid cells the pheromone pathway is not activated. In this study, we utilized diploid pathways for the initial screening, and then further evaluated the effects of our screened compounds using the haploidspecific pheromone pathway. BTB03006 acted on both diploid cells and a pheromone pathway in haploid cells, but GK03225 acted only on the diploid pathways. Pathway specificity is a vital component of our understanding of the mode of action of such compounds, since they can then be distinguished more clearly. BTB03006 probably acts directly on Ste11, or might function against a component common to the three pathways. However, GK03225 is clearly not a direct inhibitor of Ste11, and probably acts on downstream components of Ste11. Ste11 activates Ste7 MAPKK and Fus3/Kss1 MAPK in the pheromone and pseudohyphal/invasive growth pathways, but activates Pbs2 MAPKK and Hog1 MAPK in the osmosensing pathway. Therefore, the target of BTB03006 must be either Ste11 itself or a regulator of Ste11 activation. As a known regulator of Ste11 activation, the Hsp90 inhibitor radicicol was also identified in our assay system (Fig. 2) . Similar Hsp90 inhibitors such as geldanamycin, herbimycin, and 17-AAG are now used as cancer therapeutics, 42, 43) and further screening for compounds using our Ste11 activation system has the potential to identify additional Hsp90 inhibitors that might prove to be effective in anticancer chemotherapies.
GK03225 shows a specificity that is most likely to be the osmosensing pathway, since both the pseudohyphal/ invasive growth pathway and the pheromone signaling pathway utilize Ste7 MAPKK and Kss1 MAPK. Therefore, the target of GK03225 might be a specific factor that functions in the osmosensing pathway. Even though Pbs2 MAPKK and Hog1 MAPK are downstream protein kinases in the osmosensing pathway, there is a possibility that unknown downstream components are also present. To elucidate further the downstream effectors of Ste11 in diploid yeast, we performed a genome-wide screen for suppressors of this gene. Among the deletion strains that we subsequently isolated, pbs2Á and hog1Á were identified as harboring likely downstream mutations in the Ste11 pathways. In this regard also, previous studies have shown that Hsc82 and Sti1 interact with each other and have cytosolic chaperone functions. 40, 44) YGL072C encodes an unknown open reading frame, but its deletion produces a partial C-terminal deletion of HSF1 in the opposite strand, and is thus referred to as hsf1ÁC in this study. Hsf1 is known as an essential heatshock transcription factor. 45) Since several heat-shock proteins are also known to be required for full activation of Ste11, deletion of these proteins is likely to generate defects in active Ste11 formation. Bud27 is a protein involved in bud-site selection, and is synthetically lethal with Hsp82, a homolog of Hsc82, 46) suggesting that Bud27 may also be involved in Ste11 chaperoning. Hence, of a possible 4,433 strains in our deletion panel of diploid yeast strains, we identified only six putative Ste11-specific suppressors, indicating that the downstream targets of Ste11 screening are limited in number.
GK03225 has a chemical structure similar to a number of tyrosine kinase inhibitors, including PD153035, a compound that is known to inhibit receptor-type tyrosine kinases such as EGFR. 36) Hence we speculated as to whether the target of GK03225 is Pbs2 kinase, since this is a dual specificity kinase that phosphorylates tyrosine residues in Hog1. 47) Although we did not obtain conclusive results proving that GK03225 inhibits yeast protein kinases, we did find that a GK03225 analog, 11N-078, strongly suppresses Ste11-induced growth defects (Fig. 5A, Table 1 ), induces growth defects in high osmolarity media (Fig. 5B) , and also reverses the growth defects and inhibits the tyrosine phosphorylation activity induced by c-Abl in yeast (Fig. 6 ). 11N-078 is known as a v-Src kinase inhibitor, 48) suggesting that this compound is a multi kinase-targeting inhibitor. Sorafenib (BY43-90069) and Sunitinib (SU11248) are known multi kinase-targeting inhibitors that act on VEGFR, PDGFR, FLT3, and c-Kit, and have been approved by the FDA. 49) Hence 11N-078 might be a valid drug candidate. On the other hand, 11N-823 was found to suppress Ste11-induced growth defects in a manner similar to GK03225, but did not suppress c-Abl-induced growth defects. This suggests that 11N-823 and GK03225 inhibit a number of yeast protein kinases efficiently but have no effects on c-Abl kinase. In contrast, the 11N-070 analog did show inhibitory effects on in vivo tyrosine phosphorylation. 11N-070 elicited a weak toxic effect, which might reduce growth promotion by the suppression of c-Abl activation. Even though we identified a yeast protein phosphatase that enhanced cAbl-induced growth defects, and also constructed slightly active c-AblÁSH3 similar to temperaturesensitive STE11-4, we have not yet been able to apply them to develop a highly sensitive human tyrosine kinase assay method. However, submarginal growth defects induced by human tyrosine kinases in yeast should provide a high-throughput in vivo screening system for tyrosine kinase inhibitors. Structural analysis of the screened compounds and their analogs together with structural information on the target proteins and the powerful yeast genetics should reveal mechanisms of specific inhibition valuable for drug development.
In conclusion, sensitive drug screening using the yeast MAPKKK as the primary target, and evaluation of yeast signaling pathways and human c-Abl, have enabled us to gain a good deal of information regarding the mode of action of the compounds identified. In addition, genomewide suppressor screening of yeast deletion strains has provided candidate target proteins from the Ste11 activation pathways. Use of the yeast drug assay system developed here for different target proteins should allow us in the future to identify more compounds, and at the same time uncover important information regarding their mode of action and specificity.
